Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China

Ying Bai, Jianpeng Zheng, Feng Lü, Xilin Zhang, Chang-Ping Sun, Weihua Guo, Yi-Xi Zou, Gregory Y.h. Lip, Shi XuboScientific 2022 · DOI

Abstract

This study investigates the prevalence, incidence, and mortality of clinically diagnosed hypertrophic cardiomyopathy (HCM) in a Chinese population cohort of 21.9 million. Utilizing data from the Beijing Municipal Health Commission Information Center (2010–2019), we observed a significant rise in HCM prevalence (from 0.0069% to 0.076%) and incidence (from 6.85 to 11.76 per 100,000 person-years). While mortality remained relatively stable, the incidence of heart failure increased. Predictive modeling suggests that the population burden of HCM will double by 2029, emphasizing the need for enhanced clinical screening and management.

Introduction

Hypertrophic cardiomyopathy (HCM) is a primary genetic heart disease characterized by unexplained left ventricular hypertrophy. It is a major contributor to sudden cardiac death, heart failure, and stroke. Despite its clinical significance, large-scale epidemiological data for the Chinese population has been historically limited, often relying on small screening samples. This study aims to provide a comprehensive assessment of the HCM burden in Beijing, identifying demographic trends and forecasting future incidence to inform public health strategies.

Methods

The researchers utilized the Beijing Municipal Health Commission Information Center (BMHCIC) database, which aggregates clinical data from all 153 hospitals in the Beijing area. The study cohort grew from 19.62 million in 2010 to 21.90 million in 2019. HCM cases were identified via ICD-10 codes and validated by expert review. Trend analysis was conducted using Annual Percentage Change (APC), while future projections were generated using Poisson regression and the Gray Model 1,1 (GM [1,1]).

The clinical detection of HCM in Beijing saw a dramatic increase over the decade. The prevalence rose more than tenfold, reaching 0.076% by 2019. Similarly, the annual incidence of new diagnoses increased significantly.

Annual HCM incidence and population data in Beijing (2010–2019).

A notable "gender paradox" was observed: while males exhibited higher prevalence and incidence rates, females diagnosed with HCM faced a significantly higher mortality rate (4.20% vs. 2.70%, p < 0.001). Furthermore, while the individual risk of mortality remained stable during the study period, the incidence of HCM-related heart failure rose significantly (APPC: 8.4).

Future Projections

Based on the observed trends from the last decade, mathematical modeling predicts a continued surge in HCM cases. Both the Poisson regression and Gray models indicate that the number of incident HCM cases is expected to double by 2029, with projected increases ranging from 2.19-fold to 2.48-fold.

Projected HCM incidence through 2029 using Poisson and Gray models.

Discussion

The findings suggest that the current clinical prevalence (0.076%) is still below previous screening-based estimates (~0.16%), indicating a substantial "iceberg effect" where many asymptomatic individuals remain undiagnosed. The rising incidence likely reflects improved diagnostic capabilities and clinical awareness rather than a change in the underlying genetic frequency.

Limitations

The study is limited by its reliance on clinical records rather than universal genetic testing. Additionally, as a hospital-based registry, it may under-represent asymptomatic patients. Finally, while the Beijing cohort is massive, results may not fully generalize to rural regions with different healthcare access levels.

Conclusion

The burden of HCM in China is rising rapidly. With the projected doubling of cases over the next decade, there is an urgent need for proactive screening programs and improved management of HCM-related complications, particularly heart failure, to mitigate the long-term impact on public health.

Summary updated

Abstract

Abstract There are limited studies on the prevalence and incidence of clinically diagnosed hypertrophic myocardiopathy (HCM) and its mortality in the Chinese population, and the projected population burden of HCM over the next decades. We collected data on HCM and its mortality from the Beijing Municipal Health Commission Information Center (BMHCIC) database and estimated the prevalence and incidence based on the whole Beijing population. Calculation of population trends was performed using annual percentage change (APC) and average annual percentage change (AAPC). Finally, future HCM incidence was built by modelling projection of HCM to the next decades using Poisson regression analysis and Gray Model 1,1(GM [1,1]). The prevalence of HCM was 0.0069% (95%CI, 0.0065–0.0072%; N = 1343) in 2010, rising to 0.076% (95% CI, 0.074–0.077%; N = 16,616) in 2019, and the incidence of HCM was 6.85 per 100 000 person-year in 2010, rising to 11.76 per 100 000 person-year in 2019. Males had higher prevalence and incidence of HCM than females. The APPC for the rising incidence of HCM was 5.8% and the expected numbers will double increase in 2029 by assuming the same increase trend as the last decades. HCM had increased annual incidence of HF (APPC: 8.4, 4.4–12.6, p &lt; 0.05), and relatively stable annual incidence of mortality (APPC: 1.2%, − 2.3% to 4.8%, p &gt; 0.05) during the studied period. Males had lower mortality (2.70% vs. 4.20%, p &lt; 0.001) than females. The calculated HCM prevalence was much lower compared to prior screening studies from 2004, although the predicted HCM incidence would double over the next decades. HCM was associated with a stable risk of mortality during the studied period.
BibTeX
@inproceedings{bai2022prevalence,
  author = {Ying Bai and Jianpeng Zheng and Feng Lü and Xilin Zhang and Chang-Ping Sun and Weihua Guo and Yi-Xi Zou and Gregory Y.H. Lip and Shi Xubo},
  title = {{Prevalence, incidence and mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9 million in China}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-20042-9},
}
Figure